Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimization of hydroxyurea management in sickle cell disease with pharmacological therapeutic follow-up
2024-515562-14-00Phase 4Completed
- Sponsor
- Strasbourg University Hospital
- Start
- Jul 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of hydroxyurea in sickle cell disease (SCD) (2 arms), sponsored by Strasbourg University Hospital. Primary endpoint: Proportion of subjects with a time to reach LMA of less than 9 months. Started Jul 2024; status: completed.
02
Drugs
hydroxyurea
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on 2024-515562-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515562-14-00.